Muscle Preservation on Semaglutide: What the Research Says and What You Can Do About It

Here is a number worth sitting with: over 25% of the total weight lost on GLP-1 receptor agonists like semaglutide doesn’t come from fat. It comes from fat-free mass — muscle, bone, and other lean tissue. A 2024 review published in Metabolism: Clinical and Experimental by Stefanakis, Kokkorakis, and Mantzoros put that figure into stark context, noting that this rate of lean mass loss mirrors what’s seen after bariatric surgery. For men on semaglutide who are watching the scale drop with satisfaction, this is a critical piece of the picture that’s easy to miss.

Semaglutide has earned its place as a legitimate tool for significant fat loss. Clinical trials demonstrate weight reductions in the range of 15% to 25% of total body weight, and the cardiovascular, metabolic, and glycemic benefits are well-documented. Drucker’s 2025 review in Nature Reviews Drug Discovery confirmed that GLP-1-based therapies represent some of the most effective pharmacological options available for obesity and type 2 diabetes, while also flagging that the scale and speed of weight loss raises legitimate concerns for musculoskeletal health. The drug works. But how you use it — and what you do alongside it — determines whether you come out the other side leaner and stronger, or lighter and metabolically compromised.

Why Muscle Loss on Semaglutide Is a Real Problem

The mechanism behind semaglutide’s weight loss is appetite suppression. By activating GLP-1 receptors in the brain, it reduces hunger signals dramatically, leading to significant caloric restriction. That restriction is effective for fat loss, but the body doesn’t exclusively burn fat when it’s in a sustained energy deficit. Skeletal muscle becomes a target too, particularly when protein intake drops and physical activity isn’t structured to defend lean tissue.

A 2024 narrative review in Diabetes Care by Locatelli, Costa, and Haynes framed the scale of this problem in a way that’s difficult to ignore. GLP-1 receptor agonists including liraglutide, semaglutide, and tirzepatide induce lean mass losses of approximately 10%, or around 6 kilograms, in adults with obesity. The authors noted that this degree of muscle loss is comparable to what a person would experience over a decade or more of natural aging. Losing that much lean tissue at any age matters. In middle-aged and older men, the consequences compound quickly — reduced resting metabolic rate, declining strength, increased fall risk, and a setup for sarcopenic obesity, where low muscle mass and excess fat coexist in a metabolically destructive combination.

The biological machinery driving this process involves a signaling pathway centered on myostatin and activin A — proteins that inhibit muscle growth. The Stefanakis review highlighted the myostatin-activin-follistatin-inhibin system as a critical regulator of lean mass during periods of negative energy balance. In simple terms: when calories drop sharply, the body ramps up signals that break down muscle. Follistatin acts as a natural brake on that process, but it’s often overwhelmed during aggressive caloric restriction. This is the physiological reason why eating less alone — regardless of whether it’s drug-induced or voluntary — puts muscle at risk.

Real-world data from the SEMALEAN study adds important nuance here. This 2026 prospective study published in Diabetes, Obesity & Metabolism followed 115 patients with obesity through 12 months of semaglutide 2.4 mg therapy, measuring body composition via DXA scan, handgrip strength, and resting energy expenditure. The findings were more encouraging than the preclinical data might suggest: lean mass was largely preserved, and muscle function — as measured by handgrip strength — actually improved over the study period. Metabolic efficiency was maintained as well. This doesn’t contradict the concern about lean mass loss; it suggests that outcomes are highly variable and likely depend on factors like protein intake, activity level, starting body composition, and how the dose escalation is managed.

What You Can Do Right Now to Protect Your Muscle

The most powerful intervention available to any man on semaglutide — or any man in a caloric deficit, for that matter — is structured resistance training. The Locatelli review in Diabetes Care analyzed the evidence and found that supervised resistance exercise programs lasting more than 10 weeks produced lean mass gains of approximately 3 kilograms and strength improvements of around 25% in both men and women. That’s not a marginal effect. That is a meaningful biological counterweight to the muscle-depleting forces of caloric restriction.

The practical prescription here is straightforward, even if the execution requires discipline. Training three to four days per week with compound movements — squats, deadlifts, rows, presses — provides the mechanical stimulus that tells the body muscle is worth keeping. Progressive overload matters: the goal is to increase either the weight lifted or the volume performed over time, because a constant, unchanging stimulus stops being a sufficient signal for adaptation. On semaglutide, appetite suppression can make it tempting to eat very little. Protein intake needs to be a deliberate priority, not an afterthought. Most research supports a target of 1.6 to 2.2 grams of protein per kilogram of body weight daily for men trying to preserve or build lean mass during a caloric deficit.

Beyond training and protein, the emerging pharmacological science points to a future where muscle preservation during GLP-1 therapy becomes significantly more achievable. A 2024 study in Molecular Metabolism by Nunn, Jaiswal, and Gavin tested the combination of bimagrumab — a monoclonal antibody that blocks activin type II receptors — alongside semaglutide in diet-induced obese mice. The results were compelling: semaglutide alone decreased both fat and lean mass, as expected. But when bimagrumab was added, lean mass was preserved and fat mass loss was actually enhanced. The combination also improved exercise performance and metabolic outcomes. The Stefanakis review flagged similar compounds — trevogrumab and garetosmab — as promising candidates in the pipeline. These drugs aren’t widely available yet, but they signal where obesity pharmacotherapy is heading: not just weight loss, but precision body composition management.

For men who are not on any medication and are simply managing a calorie deficit through diet, none of this is fundamentally different. Caloric restriction without resistance training depletes muscle regardless of what’s causing the deficit. The physiology doesn’t care whether your appetite is suppressed by a weekly injection or by willpower. The solution is the same: lift heavy, eat enough protein, and treat muscle as a metabolic asset worth protecting.

The Takeaway

Semaglutide is a powerful tool for fat loss, and the data on its metabolic and cardiovascular benefits is real. But the drug creates conditions that challenge muscle preservation, and ignoring that comes at a cost. The research is clear that lean mass loss during significant weight loss — pharmacological or otherwise — increases the risk of sarcopenic obesity, reduces metabolic rate, and compromises physical function over the long term. The men who come out of a semaglutide cycle in the best shape are the ones who treated it as one component of a broader strategy, not the whole plan. Resistance training and adequate protein intake aren’t optional add-ons. For anyone serious about what their body looks and performs like on the other side of weight loss, they are the foundation everything else is built on.